Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

682
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
682
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

686
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
686
Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

836
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
836

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Exploring gefitinib to enhance endocytosis of antibodies and nucleic acid aptamers targeting EGFR in glioblastoma.

Nanoscale·2026
Same author

GPRASP1 deletion suppresses antinociceptive tolerance during chronic activation of delta opioid receptor in persistent pain.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2026
Same author

Divergence in μ and δ opioid receptor pharmacology in neurons and antinociceptive efficacy in neuropathic pain: Insights from MP135 and CYM51010.

British journal of pharmacology·2026
Same author

GPRASP1 deletion in mice abrogates adverse side effects associated with chronic stimulation of Beta2-adrenoceptor.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2025
Same author

Antibody-Vincristine Conjugates as Potent Anticancer Therapeutic Agents.

Journal of medicinal chemistry·2024
Same author

The Metabolically Resistant Apelin-17 Analogue LIT01-196 Reduces Cardiac Dysfunction and Remodelling in Heart Failure After Myocardial Infarction.

The Canadian journal of cardiology·2024

Related Experiment Video

Updated: Oct 18, 2025

Murine Model of Allergen Induced Asthma
08:05

Murine Model of Allergen Induced Asthma

Published on: May 14, 2012

40.6K

An Autophagy Modulator Peptide Prevents Lung Function Decrease and Corrects Established Inflammation in Murine Models

François Daubeuf1,2, Nicolas Schall3, Nathalie Petit-Demoulière1,3

  • 1CNRS-Strasbourg University Laboratoire d'Innovation Thérapeutique/Strasbourg Drug Discovery and Development Institute (IMS), Faculté de Pharmacie, 67400 Illkirch, France.

Cells
|September 28, 2021
PubMed
Summary

Autophagy dysfunction is implicated in asthma. Targeting chaperone-mediated autophagy with peptide P140 in mice reduced airway inflammation and corrected cellular alterations without affecting antibody production.

Keywords:
allergic asthmaautophagymurine modelsneutrophilspeptide-based treatment

More Related Videos

Advanced Imaging of Lung Homing Human Lymphocytes in an Experimental In Vivo Model of Allergic Inflammation Based on Light-sheet Microscopy
10:39

Advanced Imaging of Lung Homing Human Lymphocytes in an Experimental In Vivo Model of Allergic Inflammation Based on Light-sheet Microscopy

Published on: April 16, 2019

7.8K
Assessment of Respiratory Function in Conscious Mice by Double-chamber Plethysmography
08:58

Assessment of Respiratory Function in Conscious Mice by Double-chamber Plethysmography

Published on: July 10, 2018

43.4K

Related Experiment Videos

Last Updated: Oct 18, 2025

Murine Model of Allergen Induced Asthma
08:05

Murine Model of Allergen Induced Asthma

Published on: May 14, 2012

40.6K
Advanced Imaging of Lung Homing Human Lymphocytes in an Experimental In Vivo Model of Allergic Inflammation Based on Light-sheet Microscopy
10:39

Advanced Imaging of Lung Homing Human Lymphocytes in an Experimental In Vivo Model of Allergic Inflammation Based on Light-sheet Microscopy

Published on: April 16, 2019

7.8K
Assessment of Respiratory Function in Conscious Mice by Double-chamber Plethysmography
08:58

Assessment of Respiratory Function in Conscious Mice by Double-chamber Plethysmography

Published on: July 10, 2018

43.4K

Area of Science:

  • Cellular Biology
  • Immunology
  • Pulmonology

Background:

  • Autophagy's role in asthma pathogenesis remains unclear.
  • Dysfunctional autophagy is increasingly linked to inflammatory diseases.
  • Investigating autophagy markers in a house dust mite (HDM)-induced asthma model is crucial.

Purpose of the Study:

  • To investigate autophagy alterations in a murine model of allergic airway inflammation.
  • To evaluate the therapeutic potential of targeting chaperone-mediated autophagy using peptide P140.

Main Methods:

  • Utilized a chronic house dust mite (HDM)-induced asthma model in mice.
  • Assessed autophagy marker expression (sequestosome-1/p62) in lung and spleen cells.
  • Administered therapeutic peptide P140 to allergen-sensitized mice and measured airway function and inflammatory cell counts.

Main Results:

  • Sequestosome-1/p62 expression differed between splenocytes and neutrophils, indicating compartment-specific autophagy regulation.
  • P140 treatment significantly reduced airway resistance, elastance, and influx of neutrophils and eosinophils.
  • P140 corrected autophagic alterations without suppressing key allergic antibody production (IgG1, IgE).

Conclusions:

  • Autophagy processes are demonstrably altered in allergic airway inflammation.
  • Targeting chaperone-mediated autophagy with P140 shows therapeutic promise for asthma.
  • Autophagy represents a potential therapeutic target for specific asthma patient populations.